674290-09-6

Basic information

• Product Name: ethyl 4-(4-cyanophenyl)-6-methyl-2-thioxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate
• Synonyms: ethyl 4-(4-cyanophenyl)-6-methyl-2-thioxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate
• CAS NO: 674290-09-6
• Molecular Weight: 445.465
• Mol File: 674290-09-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: ethyl 4-(4-cyanophenyl)-6-methyl-2-thioxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(4-cyanophenyl)-6-methyl-2-thioxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate(674290-09-6)
• EPA Substance Registry System: ethyl 4-(4-cyanophenyl)-6-methyl-2-thioxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate(674290-09-6)

Safety Data

• Hazardous Substances Data: 674290-09-6(Hazardous Substances Data)

Upstream product

• 1736-71-6 2-trifluoromethylphenyl thiourea 
• 141-97-9 ethyl acetoacetate 
• 105-07-7 4-cyanobenzaldehyde 

Downstream Products

• 674290-27-8 ethyl 4-(4-cyanophenyl)-6-methyl-2-[(3-pyridinylmethyl)sulfanyl]-1-[3-(trifluoromethyl)phenyl]-1,4-dihydro-5-pyrimidinecarboxylate 
• 674290-30-3 ethyl 4-(4-cyanophenyl)-2-[(1H-imidazol-2-ylmethyl)sulfanyl]-6-methyl-1-[3-(tri-fluoromethyl)phenyl]-1,4-dihydro-5-pyrimidinecarboxylate 
• 674290-26-7 ethyl 4-(4-cyanophenyl)-6-methyl-2-[(4-pyridinylmethyl)sulfanyl]-1-[3-(trifluoromethyl)phenyl]-1,4-dihydro-5-pyrimidinecarboxylate 
• 674290-25-6 ethyl 4-(4-cyanophenyl)-6-methyl-2-(butylsulfanyl)-1-[3-(trifluoromethyl)phenyl]-1,4-dihydro-5-pyrimidinecarboxylate 
• 674290-22-3 ethyl 4-(4-cyanophenyl)-6-methyl-2-(ethylsulfanyl)-1-[3-(trifluoromethyl)phenyl]-1,4-dihydro-5-pyrimidinecarboxylate 
• 674290-28-9 ethyl 4-(4-cyanophenyl)-6-methyl-2-{[2-(diethylamino)ethyl]sulfanyl}-1-[3-(trifluoromethyl)phenyl]-1,4-dihydro-5-pyrimidinecarboxylate 

Relevant articles and documents

HETEROCYCLIC DERIVATIVES

The invention relates to novel heterocyclic derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart